This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Human IL-29 / IFN-lambda 1 Protein, His Tag
catalog :
IL9-H4228
quantity :
50 ug, 20 ug
price :
450 USD, 198 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
IL9-H4228
product name :
Human IL-29 / IFN-lambda 1 Protein, His Tag
quantity :
50 ug, 20 ug
price :
450 USD, 198 USD
quantity & price :
$198/20ug,$450/50ug
target :
IL-29
host species :
Human
By Tag :
His Tag
Research :
For Research Use Only
Source :
Human IL-29, His Tag (IL9-H4228) is expressed from human 293 cells (HEK293). It contains AA Gly 20 - Thr 200 (Accession # NP_742152.1).
Endotoxin :
Less than 1.0 EU per μg by the LAL method.
Purity :
>95% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Human IL-29, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Formulation :
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
Reconstitution :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
Background :
Interleukin-29, is a secreted protein which belongs to the IL-28 / IL-29 family, and is a type III interferon. It is also known as cytokine Zcyto21, Interferon lambda-1, IFN-lambda-1, IFNλ1, IL-29 and IFNL1, and is highly similar in amino acid sequence to the IL-28, the other type III interferon. IL28A, IL28B, and IL29, also named interferonλ2 (IFNλ2), IFNλ3, and IFNλ1, respectively, are classII cytokine receptor ligands that are distantly related to members of the IL 10 family (11-13% aa sequence identity) and the type I IFN family (15-19% aa sequence identity). Human IL29 cDNA encodes a 200 amino acid (aa) residue precursor protein with a putative 19 aa signal peptide and a 181 aa mature protein, which is a monomer in solution. It shares 67% and 69% aa sequence identity with human IL28A and IL28B, respectively. IL-29 plays an important role in host defenses against microbes and its gene is highly upregulated in cells infected with viruses and also may play a role in antiviral immunity. Interleukin-29 / IL-29 up-regulates MHC class I antigen expression. It is a Ligand for the heterodimeric class II cytokine receptor composed of IL10RB and IL28RA. The ligand/receptor complex seems to signal through the Jak-STAT pathway.
References :
(1) Sheppard P., et al., 2003, Nat. Immunol. 4:63-68.
(2) Kotenko S.V., et al., 2003, Nat. Immunol. 4:69-77.
(3) Vilcek J et al., 2003, Nat. Immunol. 4 (1): 8-9.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments